Morse

Morse is pleased to have supported the Myeloma Investment Fund (MIF) in its investment in Envisagenics, a biotechnology company pioneering the development of RNA splicing technology. The Myeloma Investment Fund, a subsidiary of the Multiple Myeloma Research Foundation (MMRF), views this investment in Envisagenics as a key opportunity to advance multiple myeloma research, and to pave the way for new treatments for the myeloma community

Read more here.